TOP TEN perturbations for Q9Y2F9 (Homo sapiens)
Organism: Homo sapiens
Gene: Q9Y2F9
Selected probe(set): 202946_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of Q9Y2F9 (202946_s_at) across 5880 perturbations tested by GENEVESTIGATOR:
OPM-1 / MM1.S
Relative Expression (log2-ratio):-5.0969696Number of Samples:4 / 4
| Experimental | OPM-1 |
| Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code: | |
| Control | MM1.S |
| Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code: |
bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Relative Expression (log2-ratio):-3.622017Number of Samples:2 / 2
| Experimental | bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted). | |
| Control | bone cancer study 1 (PDX; myxoid chondrosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted). |
CAR T cell study 4 (PSCA-28t28Z; post-infusion) / CAR T cell study 4 (PSCA-28t28Z; pre-infusion)
Relative Expression (log2-ratio):-3.464179Number of Samples:3 / 3
| Experimental | CAR T cell study 4 (PSCA-28t28Z; post-infusion) |
| CD8+ T cells transduced with PSCA-28t28Z (second generation CAR) and isolated 30 days after adoptive transfer into mice bearing HPAC-derived pancreatic tumor. Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2 and then transfered into 4-5-week-old male NSG mice. Subcutaneous xenografts were generated by injection of HPAC cells. Once tumors became palpable, mice were treated with CD8+ T cells expressing PSCA-28t28Z. Untransduced CD4+ cells from the same donor were given to each mouse for cytokine support. Spleen-resident human CD8+ T cells were isolated 30 days later using the CD8 MicroBeads (post-infusion samples). | |
| Control | CAR T cell study 4 (PSCA-28t28Z; pre-infusion) |
| Primary human CD8+ T cells stimulated ex vivo and transduced to express PSCA-28t28Z (second generation CAR). Human peripheral blood mononuclear cells were stimulated with anti-CD3 antibody (OKT3) in presence of IL-2. Two days post-stimulation, T cells were transduced with retroviral vectors encoding PSCA-28t28Z. Cells were cultured for 2 weeks in presence of IL-2, until collection of samples (pre-infusion samples). |
immune cell study 6 (PB; memory) / immune cell study 6 (PB; CD21lo)
Relative Expression (log2-ratio):-3.4355087Number of Samples:2 / 2
| Experimental | immune cell study 6 (PB; memory) |
| Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+. | |
| Control | immune cell study 6 (PB; CD21lo) |
| Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21lo) isolated from peripheral blood (PB) B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21lo. |
CML study 1 / B-CLL study 5
Relative Expression (log2-ratio):3.3802233Number of Samples:75 / 441
| Experimental | CML study 1 |
| Bone marrow samples of patients with chronic myeloid leukemia (CML). | |
| Control | B-CLL study 5 |
| Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary)
Relative Expression (log2-ratio):-3.2738924Number of Samples:2 / 3
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). |
lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):3.1695347Number of Samples:4 / 3
| Experimental | lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |
immune cell study 6 (PB; memory) / immune cell study 6 (PB; CD21hi)
Relative Expression (log2-ratio):-3.1621075Number of Samples:2 / 2
| Experimental | immune cell study 6 (PB; memory) |
| Memory B-cells (CD20+/CD10-/CD27+) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27+. | |
| Control | immune cell study 6 (PB; CD21hi) |
| Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21hi) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21hi. |
immune cell study 6 (PB; naive) / immune cell study 6 (PB; CD21lo)
Relative Expression (log2-ratio):-3.1202402Number of Samples:2 / 2
| Experimental | immune cell study 6 (PB; naive) |
| Naive B-cells (CD20+/CD10-/CD27-) isolated from peripheral blood (PB). B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10-/CD27-. | |
| Control | immune cell study 6 (PB; CD21lo) |
| Immature (transitional) B-cells (CD20+/CD10+/CD27-/CD21lo) isolated from peripheral blood (PB) B-cells were isolated by negative selection, labeled with mAb specific for CD20, CD10, CD21, and CD27 and sorted for CD20+/CD10+/CD27-/CD21lo. |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; large cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.9013615Number of Samples:2 / 4
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted). |